Season 3 - Ep.19: Big data in cardiology - Measuring lipids: what clinicians need to know

6 snips

Jul 3, 2025

Carlos Aguiar, a notable cardiologist, dives into the transformative influence of big data in cardiology. He discusses the integration of AI in echocardiography and the potential survival benefits of surgical interventions for atrial fibrillation. Aguiar highlights the significant biases surrounding lipid measurements and the importance of inclusive data collection. The conversation also touches on the cardiovascular risks associated with cannabis use and advances in cardiac imaging, particularly the role of lipoprotein(a) as a genetic risk factor.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Big Data's Holistic Cardiac Potential

Big data integrates diverse clinical, imaging, genomics, and wearable data for a holistic cardiovascular patient view.
Challenges include noise, heterogeneity, and biases especially in patient data representation.

ADVICE

Address Bias in Cardiovascular AI

Collect inclusive datasets to address biases in AI tools, especially regarding sex, socioeconomic, and education disparities.
Promote policies and incentives to ensure AI reflects all patient subgroups fairly.

INSIGHT

Fasting Lipid Tests Context

Non-fasting lipid tests are adequate for most patients with minimal differences compared to fasting tests.
Fasting is recommended for specific groups like those with diabetes, obesity, or high triglycerides for accuracy.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
Big data in cardiology
Measuring lipids: what clinicians need to know
Milestones

Host: Perry Elliott

Guests: Carlos Aguiar, Karim Lekadir, Kostas Koskinas

Want to watch that episode? Go to: https://esc365.escardio.org/event/1808

Disclaimer:

ESC TV Today is supported by Bristol Myers Squibb and Novartis.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

The ESC is not liable for any translated content of this video. The English-language always prevails.

Declarations of interests:

Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

Kostas Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from MSD, Daiichi-Sankyo.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.